Central blockade of oxytocin receptors during mid-late gestation reduces amplitude of slow afterhyperpolarization in supraoptic oxytocin neurons.

The neurohypophysial hormone oxytocin (OT), synthesized in magnocellular paraventricular (PVN) and supraoptic (SON) nuclei, is well known for its effects in lactation. Our previous studies showed that central OT receptor (OTR) binding is increased during gestation and that blockade of central OTRs, specifically during mid-late gestation, causes a delay in OT release during suckling and reduces weight gain in pups, suggesting decreased milk delivery. In the present study, we tested whether central OTR blockade during late gestation disrupts the gestation-related plasticity in intrinsic membrane properties. Whole cell current-clamp recordings were performed in OT neurons from pregnant rats (19-22 days in gestation) that were infused with an OTR antagonist (OTA) or artificial cerebrospinal fluid (aCSF) and from virgin rats infused with aCSF into the third ventricle via an osmotic minipump beginning on days 12-14 of gestation. The amplitudes of both Ca(2+)-dependent afterhyperpolarizations (AHPs), an apamin-sensitive medium AHP (mAHP) and an apamin-insensitive slow AHP (sAHP), were significantly increased during late gestation in control pregnant animals. However, the amplitude of the sAHP from pregnant rats treated with the OTA was significantly smaller than that of pregnant control rats and similar to that of virgins. These results indicate that the diminished efficiency in lactation due to OTR blockade may be partly a result of an altered sAHP that would shape OT bursting. These findings suggest that central actions of OT during late gestation are necessary for programming the plasticity of at least some of the intrinsic membrane properties in OT neurons during lactation.

Neuroendocrine actions and regulation of hypothalamic neuropeptide Y during lactation.

The expression of neuropeptide Y (NPY) and its co-messenger, agouti-related peptide (AgRP), in arcuate neurons of the hypothalamus is increased during lactation in rats. Our research has been addressing the questions of the physiological actions of these peptides during lactation and the physiological signals associated with lactation that result in increased expression of their genes. Our studies indicate that NPY and AgRP exert pleiotropic actions during lactation that help integrate neuroendocrine regulation of energy balance with controls over anterior and posterior pituitary hormone secretion. Further, reciprocal signaling to the NPY/AgRP system by leptin and ghrelin is responsible for the changes in expression of these hypothalamic peptides in lactating animals, and thus, may contribute to regulation of food intake and the various neuroendocrine adaptations of lactation.

Neurochemical bases of plasticity in the magnocellular oxytocin system during gestation.

The central and systemic release of oxytocin (OT) has been well documented during parturition and lactation. In preparation for the demands of these events, the magnocellular hypothalamic neurons of the central OT system undergo a variety of biochemical, molecular, electrophysiological, and anatomical adaptations during gestation. However, the mechanisms responsible for these changes have not been well established. A number of neurochemical mediators have been implicated in contributing to the plasticity in the OT magnocellular system during gestation, including ovarian hormones, as well as central neurotransmitters, such as glutamate, gamma-amino butyric acid (GABA), and central neurosteroids, e.g., allopregnanolone. In addition, several lines of evidence suggest that central OT release and subsequent OT receptor stimulation may contribute to adaptations of the OT system during gestation, and may be necessary for its subsequent functioning during lactation. Here, we review evidence for involvement of the neurochemical systems implicated in contributing to adaptations that occur in the OT system during the course of gestation.

Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats.

Relatively little is known concerning the interaction of psychostimulants with hypothalamic neuropeptide systems or metabolic hormones implicated in regulation of energy balance. The present studies tested whether methamphetamine alters the expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP), two important orexigenic neuropeptides, or proopiomelanocortin (POMC), the precursor for the anorexigenic peptide alpha-melanocyte-stimulating hormone, or the secretion of leptin, insulin and ghrelin, concomitant with inhibition of food intake. Female rats were either fed ad libitum (AL) or placed on a scheduled feeding (SF) regimen, with access to food limited to 4 h/day. Administration of (+/-)-methamphetamine (7.5 mg/kg, i.p.) 2 h prior to food presentation significantly inhibited food intake in SF animals, but did not affect intake in AL animals. In a separate study, AL and SF animals were killed just prior to expected food presentation, and expression of NPY, AgRP and POMC mRNAs in hypothalamus was determined using in situ hybridisation; concentrations of leptin, insulin and ghrelin in serum were determined with radioimmunoassays. In saline-treated, SF controls, NPY and AgRP mRNA expression in arcuate nucleus and serum ghrelin were significantly elevated, and serum leptin and insulin were significantly reduced. Methamphetamine reversed the up-regulation of NPY mRNA expression observed in the SF condition, without affecting AgRP mRNA or the serum concentrations of metabolic hormones. However, in AL animals, NPY mRNA expression in arcuate and dorsomedial nuclei was significantly increased by methamphetamine, which also reduced serum leptin and insulin and increased serum ghrelin concentrations. These findings suggest that the inhibition of NPY expression in SF animals may be a mechanism underlying the anorexigenic effect of methamphetamine seen in this condition. The increase in NPY expression produced by methamphetamine in AL animals may be mediated by the ability of this drug to decrease secretion of leptin and insulin and increase secretion of ghrelin.

Role of leptin in orexigenic neuropeptide expression during lactation in rats.

The expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP), both of which are important neuropeptides involved in regulation of energy balance and hormone secretion, is up-regulated in the arcuate nucleus during lactation in rodents. The present study tested whether reductions in circulating insulin and/or leptin that occur in lactation provide the critical signals to these systems. Lactating female rats received 3-day infusions of either bovine insulin or recombinant rat leptin via Alzet Osmotic minipumps implanted subcutaneously in regimens designed to restore serum concentrations of these hormones to the higher non-lactating level. Compared to non-lactating rats in diestrus, lactating rats displayed significantly lower serum concentrations of insulin and leptin, and significantly increased NPY peptide concentrations in the paraventricular nucleus (PVN) and median eminence, and AgRP mRNA in the arcuate nucleus. Infusion of leptin in lactating females significantly increased serum concentrations of leptin and significantly reduced NPY concentrations in the PVN and median eminence, and decreased NPY and AgRP mRNAs in the arcuate nucleus. The same effects were produced by infusion of insulin in lactating rats, which restored both insulin and leptin concentrations in serum. The levels of pro-opiomelanocortin mRNA in the arcuate nucleus were not different in non-lactating and lactating females, and were not altered by leptin or insulin treatment. These findings support the hypothesis that the reduction in circulating leptin during lactation contributes to increased expression of NPY and AgRP in hypothalamic systems involved in the behavioural and neuroendocrine adaptations to lactation.

Central blockade of oxytocin receptors during late gestation disrupts systemic release of oxytocin during suckling in rats.

There is evidence that the central oxytocin system is activated and undergoes reorganization before parturition. The present study was designed to determine the effects of central oxytocin receptor blockade during late gestation on parturition, pup growth, and oxytocin release during suckling. Female Sprague-Dawley rats were implanted on gestation day 12-14 with Alzet osmotic minipumps containing an oxytocin receptor antagonist (d(CH2)5, Tyr(Me)(2), Orn(8)-vasotocin; OT-X) or artificial cerebrospinal fluid (VEH), which was infused into the third cerebral ventricle. Pumps were removed within 24 h of parturition. Daily maternal body weight and food intake were monitored during gestation and lactation. The length of gestation, duration of parturition, pup number, litter weight and interbirth interval were recorded. Subsequently, pup number and litter weights were recorded daily until lactation day 10 or 11, when maternal and pup behaviour, and plasma oxytocin concentration before and during suckling were measured. Central oxytocin blockade had no effect on the timing of parturition, maternal behaviour, litter size, still births, or litter weights at birth. However, beginning on day 3 of lactation, average weights of litters of OT-X females were significantly lower than litters of VEH-treated females. Furthermore, while basal plasma oxytocin concentrations, oxytocin increases in response to suckling and dam/pup interactions did not differ between groups, a significant delay in suckling-induced systemic oxytocin release was observed in OT-X females. Finally, OT-X dams weighed less than VEH dams during the postpartum observation period, although food intakes were similar. These data suggest that central actions of oxytocin during late gestation are necessary for the normal timing of systemic release of oxytocin during suckling, normal pup weight gain, and maintenance of maternal body weight.

Histaminergic control of oxytocin release in the paraventricular nucleus during lactation in rats.

The central neurotransmitters regulating both systemic and central release of oxytocin (OT) during lactation are not completely defined. Although central histaminergic systems have been implicated in systemic release of OT, the role of this neurotransmitter in suckling-induced intranuclear OT secretion has not been investigated. Therefore, microdialysis of the paraventricular nucleus (PVN) was used to determine if suckling stimulates histamine release within the PVN and if nursing-induced intranuclear OT release is reduced by local blockade of either H1 or H2 histamine receptors. Female Holtzman rats were implanted with microdialysis probes adjacent to the PVN on lactation days 8-12. The next day, the pups and dam were separated for 4 h, reunited, and again separated. Histamine concentrations in dialysates were measured before, during, and following suckling. In separate animals, a similar separation/reunion paradigm was used, but the dialysate OT concentration was measured during PVN perfusion with vehicle or an H1 or H2 receptor antagonist. Suckling increased dialysate concentrations of both histamine and OT in the PVN. Furthermore, local pharmacological blockade of either H1 or H2 receptors prevented the increase in OT release in the PVN during suckling. These data demonstrate that activation of histamine receptors in the PVN is necessary for intranuclear release of OT induced by suckling and extend previous findings demonstrating a similar relationship between central histamine and systemic release of OT.

Characterization of rabbit kidney and brain pancreatic polypeptide-binding neuropeptide Y receptors: differences with Y1 and Y2 sites in sensitivity to amiloride derivatives affecting sodium transport.

Sites sensitive to human and rat pancreatic polypeptides (hPP and rPP) accounted for more than 30% of the specific binding of [125I](Leu31,Pro34) human peptide YY (LP-PYY) in particulates from rabbit kidney cortex, and about 10% of the specific binding in membranes from rabbit hypothalamus. The binding of [125I]hPP or [125I]rPP showed a high-affinity displacement with either hPP, rPP, LP-PYY, neuropeptide Y or peptide YY (Ki below 50 pM for all), while being quite insensitive to Y2-selective ligands. The PP binding had a high sensitivity to alkali cations and inhibitors of phospholipase C, very similar to that of LP-PYY binding 'masked' by excess cold hPP. However, as different from the Y1-like LP-PYY binding, but similar to the binding of the Y2-selective ligand [125I]human peptide YY(3-36) (hPYY(3-36)), the PP binding showed a low sensitivity to guanosine polyphosphates. The PP binding was much more sensitive to N5-substituted amiloride inhibitors of Na+ transport than the binding of LP-PYY, or that of hPYY(3-36). The inhibition of PP binding by N5-substituted amilorides was not enhanced by guanine nucleotides or by phospholipase C blockers. However, pairing of N5-substituted amilorides disproportionately increased the inhibition of hPP binding. Thus, in rabbit kidney or hypothalamus, the high-affinity PP-responding sites share some of the basic properties of the Y1 and Y2 sites, but are distinguished from both by a high sensitivity to compounds affecting sodium transport. These PP/NPY receptors could associate with membrane structures involved in the control of ion balance and osmotic responses.

Stimulation of central and systemic oxytocin release by histamine in the paraventricular hypothalamic nucleus: evidence for an interaction with norepinephrine.

Central histaminergic neurons have been implicated in the control of oxytocin (OT) secretion in various physiological conditions, including parturition and lactation. The present studies investigated whether histamine also influences the central intranuclear release of OT, which is known to be important in the activation of OT neurons, and the possible interaction of histamine with norepinephrine in systemic and central OT release. Microdialysis probes were placed immediately adjacent to the hypothalamic paraventricular nucleus (PVN) and used for administration of artificial cerebrospinal fluid (ACSF) vehicle, ACSF containing histamine, ACSF containing histamine in combination with a specific H1 or H2 histamine receptor antagonist, or ACSF containing histamine and the alpha-adrenergic antagonist phentolamine. Dialysates and plasma were collected, and OT concentrations were determined using RIA. Dialysis of the PVN with ACSF containing histamine significantly increased the release of OT systemically and centrally within the PVN. Furthermore, the increases in OT concentration in dialysates and plasma were prevented by simultaneous administration of chlorpheniramine (an H1 receptor antagonist) or ranitidine (an H2 receptor antagonist) as well as by the adrenergic antagonist phentolamine. These data demonstrate that histamine acts within the PVN to increase both systemic and intranuclear release of OT. Furthermore, the increased OT release induced by histamine is dependent upon stimulation of both H1 and H2 histaminergic receptors and subsequent activation of alpha-noradrenergic receptors. These findings suggest that histamine induces systemic and intranuclear OT release by stimulating the release of norepinephrine.

Toward Multifactorial Hypothalamic Regulation of Anterior Pituitary Hormone Secretion.

The hypothalamus regulates the secretion of anterior pituitary hormones via release of releasing hormones into the hypophysial portal vasculature. Additional neuromessengers act at the pituitary to modulate responses to the hypothalamic hormones. For example, neuropeptide Y enhances the effect of gonadotropin-releasing hormone and the response to the prolactin-inhibiting hormone dopamine.

Neurotransmitter interaction in release of intranuclear oxytocin in magnocellular nuclei of the hypothalamus.

Oxytocin (OT) is released within the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus in response to several stimuli. However, the neurotransmitters that control this intranuclear OT release are unknown. In vivo microdialysis was used to examine the roles of norepinephrine and histamine in intranuclear OT release in conscious, lactating female rats. Administration of alpha- or beta-noradrenergic agonists, or histamine, increased OT release in the PVN. In addition, the increase in PVN OT evoked by exogenous histamine was prevented by simultaneous blockade of either H1 or H2 receptors. Furthermore, histamine-induced release of intranuclear OT was also prevented by blockade of alpha-adrenergic receptors. Finally, the increase in magnocellular OT release induced by suckling was abolished by administration of alpha-adrenergic antagonists. These data demonstrate that norepinephrine and histamine are important neurotransmitters for release of intranuclear OT, and histamine releases intranuclear OT by stimulating norepinephrine release.

Characterization of Y1, Y2 and Y5 subtypes of the neuropeptide Y (NPY) receptor in rabbit kidney. Sensitivity of ligand binding to guanine nucleotides and phospholipase C inhibitors.

The binding of two peptide YY/neuropeptide Y analogues selective for major subtypes of neuropeptide Y (NPY) receptors was compared in particulates from rabbit kidney cortex employing modulators of activity of G-proteins, phospholipase enzymes, and ion channels. The binding of (Leu31,Pro34)human peptide YY resembled the patterns observed previously for the brain tissue Y1 receptor, exhibiting a high sensitivity to monovalent cations, disulfide disruptors, guanosine polyphosphates and phospholipase C inhibitors. However, this binding was bimodal in response to human pancreatic polypeptide and to peptides selective for the Y2 subtype of the NPY receptor, displaying a large component pharmacologically similar to the brain Y5 receptor. This kidney Y5-like binding largely shared the sensitivity to monovalent cations, guanine nucleotides and phospholipase C inhibitors found for either the kidney or the brain Y1 receptor, and also was activated by Ca2+ ion. Both Y1- and Y5-like binding in the kidney displayed a uniformly low reactivity to a nonpeptidic Y1 antagonist, BIBP-3226, and to a receptor peptide mimetic, mastoparan analogue MAS-7. The kidney Y2 binding shared the low sensitivity to ionic environment observed for the brain Y2 subtype, and was only partially sensitive to guanine nucleotides or to MAS-7. The Y2 liganding had a sensitivity to phospholipase C inhibitors similar to the Y1/Y5 binding. This reactivity was retained in the fraction of the Y2 receptor persisting detergent solubilization in a high-affinity form, which, however, was activated rather than inhibited by G-protein agonists.

Cytoarchitectonic analysis of Fos-immunoreactivity in brainstem neurones following visceral stimuli in conscious rats.

Visceral inputs to the brain make their initial synapses within the nucleus of the solitary tract (NTS), where information is relayed to other brain regions. These inputs relate to markedly different physiological functions and provide a tool for investigating the topography of visceral processing in brainstem nuclei. Therefore, Fos immunoreactivity was used to determine whether a gastric stimulus affects neurones within different or similar parts of the NTS, ventrolateral medulla (VLM) and parabrachial nucleus (PBN), compared to a baroreceptive stimulus. The contribution of catecholaminergic neurones in these areas was studied by combining Fos and tyrosine hydroxylase (TH) immunoreactivity. Conscious male rats received either cholecystokinin (CCK) intraperitoneally to activate gastrointestinal afferents, or were made hypertensive by intravenous infusion of phenylephrine (PE) to activate baroreceptors. Tissue sections were processed immunocytochemically for Fos and/or TH. Phenylephrine infusion and CCK injection elicited Fos expression in distinct and in overlapping regions of the NTS and the VLM. Cholecystokinin injections increased the number of Fos-immunoreactive neurones in the area postrema (AP) and throughout the rostral-caudal extent of the NTS, including commissural neurones and the medial subnuclei. Some reactive neurones in NTS were also positive for TH, but most were not, and most of the TH-positive NTS neurones were not Fos-positive. In contrast, PE infusion produced a more restricted distribution of Fos-positive neurones in the NTS, with most neurones confined to a dorsolateral strip containing few TH-positive neurones. The medial NTS at the level of the AP and the AP itself were largely unresponsive, but rostral to the AP the medial NTS was labelled, including some TH-positive neurones. Both treatments produced labelling in the caudal and mid-VLM, but PE infusion had a stronger effect in the rostral VLM. In the PBN, CCK elevated Fos expression in several subregions, whereas PE infusion failed to specifically alter any subdivision. The results suggest that stimulation of baroreceptor and gastric afferents evoke both overlapping and cytoarchitectonically distinct pathways in the brainstem.

Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.

Binding of a Y1-subtype-selective agonist of neuropeptide Y (NPY) receptor, (Leu31,Pro34)human peptide YY (LP-PYY), to particulates from four rat brain areas (parietal cortex area 1, piriform cortex, anterior hypothalamus and hippocampus) showed a distinct response to LP-PYY and PYY, a uniformly low sensitivity to ligands selective for the Y2, Y4 and Y5 NPY receptor subtypes and high sensitivity to a Y1 site-selective antagonist, BIBP-3226. The Y1 binding was sensitive to guanine nucleotide-binding protein (G protein) agonist and antagonist nucleotides, with the rank order of guanosine 5'-O-(thiotriphosphate) (GTP gamma S) > GTP > GDP > guanosine 5'-O-(thiodiphosphate). However, guanine nucleotides did not affect about one third of the specific Y1 binding. Most of Y1 binding could be inhibited by a G protein nucleotide site/docking site receptor mimic, mastoparan analog MAS-7. In all areas examined, the Y1 binding of LP-PYY was little affected by up to 100 microM of the antagonists of K+, Na+ and Ca++ channels, protein kinase C, phospholipase A2, phospholipase D and phosphatidylinositol 3-kinase, phospholipase substrate phospholipids, steroids or detergents. However, the binding was potently inhibited by phospholipase C inhibitors (especially the aminosteroid U-73122), which also dissociated the bound Y1 ligand in steady-state conditions. U-73122 also displaced the Y1 binding insensitive to GTP gamma S. Ligand association with the brain Y1 NPY receptor thus strongly depends on activity of both G proteins and phospholipase C, implying specific interactions of these transducers/effectors with the receptor molecule in ligand binding. A portion of brain Y1 sites could be directly coupled to phospholipase(s) C.

Noradrenergic control of central oxytocin release during lactation in rats.

Noradrenergic systems regulate the systemic release of oxytocin (OT) in lactating rats. However, a role for norepinephrine (NE) in release of OT within the magnocellular nuclei during suckling has not been established. These studies were designed to determine 1) if suckling induces NE release in the supraoptic (SON) and paraventricular (PVN) nuclei of conscious rats and 2) the role of NE in the central, intranuclear release of OT within these nuclei. Female Holtzman rats were implanted with microdialysis probes adjacent to the PVN or SON on lactation days 8-12. The following day, the pups were isolated from the dams for 4 h. Microdialysis probes were perfused with artificial cerebrospinal fluid (ACSF) or with ACSF containing an alpha- or a beta-adrenergic receptor antagonist. Dialysate was collected before, during, and after suckling and analyzed for NE or OT. In an additional experiment, an alpha- or beta-adrenergic agonist was administered via the microdialysis probes into the PVN in nonsuckled, lactating rats. Extracellular NE increased in the PVN during suckling but was not detectable in the SON. OT concentrations in dialysates from the PVN and SON significantly increased during suckling. Blockade of either alpha-(in both PVN and SON) or beta- (PVN) adrenergic receptors prevented the suckling-induced increase in central OT release. OT release was increased in nonsuckled, lactating rats by central application of either an alpha- or beta-adrenergic agonist. These data demonstrate that intranuclear NE release is increased in the PVN by suckling and that subsequent stimulation of both alpha- and beta-noradrenergic receptors mediates intranuclear OT release.

An interactive physiological role of neuropeptide Y and galanin in pulsatile pituitary luteinizing hormone secretion.

Both neuropeptide Y (NPY) and galanin (GAL) systems have been implicated in the excitatory regulation of pulsatile LH secretion in the ovariectomized rat. The present studies were designed to examine the possible interaction of these two neuropeptides in controlling episodic LH release by testing the effects of central infusion of antibodies (Ab) to NPY and GAL, alone or in combination; additional studies tested the effects of central administration of an antisense oligodeoxynucleotide (ODN) to NPY and GAL messenger RNA. Rats were ovariectomized, implanted with a cannula in the third ventricle, and used in experiments 2 weeks later. Central infusion, via Alzet osmotic minipumps, of IgG purified from an NPY Ab produced a dose-related suppression of pulsatile LH secretion. Although an Ab dilution of 1:10 was ineffective, a maximal inhibitory effect was obtained using an NPY Ab dilution of 1:1, which decreased the mean levels, pulse frequency, and pulse amplitude of LH. These parameters of episodic LH secretion were also significantly reduced by central injection of antisense NPY ODN compared to those in vehicle- or missense ODN-treated controls. Similar dose-related inhibitory effects on the parameters of LH secretion were seen after central infusion of GAL Ab. Furthermore, infusion of a combination of NPY Ab and GAL Ab, each at the ineffective dilution of 1:10, resulted in a profound inhibition of LH secretion equivalent to the pattern seen with the maximally effective 1:1 Ab dilution. These results strengthen the idea of a physiological role for both NPY and GAL systems in the mechanism underlying the LHRH pulse generator activity and further suggest that these two excitatory neuropeptides act in concert to generate pulsatile LHRH release.

Differences in cation sensitivity of ligand binding to Y1 and Y2 subtype of neuropeptide Y receptor of rat brain.

The binding of selective ligands to the Y1 subtype of neuropeptide Y receptor in rat brain particulates was promoted by Ca2+ and also stimulated by Sr2+, but reversibly reduced by Ba2+, Mg2+, Mn2+, by the organic polycations neomycin and spermidine, and by chelating agents. The alkali monovalent cations inhibited the Ca(2+)-enabled Y1 subtype binding with some selectivity (Cs+ > or = NH4+ > Li+ > Na+, K+), with half-inhibition between 70-120 mM. The specific Y2 subtype binding was enhanced by all alkaline-earth divalent cations, Mn2+, neomycin and spermidine in the range of 0.1-10 mM, and by alkali cations at up to 100 mM, and also by Na+ salts of the chelators EGTA and EDTA. The large disparity in cation sensitivity indicates substantial differences in the structure of the binding sites of the Y1 and Y2 receptors, predictable from known distinct features of ligand epitopes and of primary structure of the receptors.

Neuropeptide Y Y2 receptors in hypothalamic neuroendocrine areas are up-regulated by estradiol and decreased by progesterone cotreatment in the ovariectomized rat.

Central neuropeptide Y (NPY) systems are known to stimulate, via the Y1 subtype of NPY receptor, the release of LHRH that leads to surges of LH. Levels of NPY receptors in relation to the above modulation have not been assessed. This study, therefore, examined profiles of NPY receptors in ovariectomized (Ovx) rats and in Ovx rat treated with estradiol (E2) with or without cotreatment with progesterone (P4). [125I]Human PYY containing proline in position 34 [(Pro 34 )hPYY] was used as the Y1 receptor ligand, and [125 I]human peptide YY-(3-36) [hPYY-(3-36)] was used as the Y2 site ligand. Treatment with E2 over 3 days increased Y2 binding in the preoptic hypothalamus and the medial basal hypothalamus, whereas no changes were found in the lateral anterior hypothalamus or the piriform cortex. Administration of P4 (1.5 mg/animal) on the third day of E2 treatment reduced Y2 binding in both the preoptic hypothalamus and the medial basal hypothalamus to or below the density found in Ovx controls. The Y1 receptor levels and the affinity of either Y1 or Y2 binding did not change appreciably with any of the treatments. No significant changes in the binding of wheat germ agglutinin were found at the time of the largest reduction in Y2 receptor numbers by P4, indicating the absence of a major membrane receptor reduction in response to the progestin. The down-regulation of Y2 sites by P4 preceded and accompanied the surge of serum LH induced by the progestin in E2-treated animals. A short term P4 treatment thus appears to reduce the Y2 tone in hypothalamic areas involved in LHRH secretion. This reduction might reinforce Y1 drives known to stimulate the output of LHRH, and thus contribute to LH release.

Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression.

Near total striatal dopamine denervation results in a decrease in substance P and an increase in enkephalin messenger RNA expression in the striatum. It is unknown whether partial depletions of striatal dopamine content produce similar changes in these peptide messenger RNAs. To test whether compensations in dopamine synthesis and release following partial dopamine denervation prevent the lesion-induced alterations in substance P and enkephalin messenger RNAs, varying concentrations of 6-hydroxydopamine were injected unilaterally into the substantia nigra. Seven days after injection of 6-hydroxydopamine (2-16 micrograms) or vehicle, in situ hybridization histochemistry was used to examine tyrosine hydroxylase messenger RNA in the substantia nigra and substance P and enkephalin messenger RNAs in the striatum. The extent of the dopamine depletion was determined by measuring striatal dopamine tissue content. The decrease in tyrosine hydroxylase messenger RNA paralleled the change in striatal tissue dopamine content. Substance P messenger RNA was decreased in all lesioned rats. In contrast, a significant increase in enkephalin messenger RNA was not detected until striatal dopamine was reduced to 10% of control levels. These results suggest that compensations within the residual dopamine system are not sufficient to maintain normal striatal substance P messenger RNA levels in partially denervated animals, but are sufficient to maintain normal striatal enkephalin messenger RNA expression.

Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for interactions with dopamine through inhibitory coupling to calcium entry.

Expression of neuropeptide Y (NPY) in the medial basal hypothalamus is increased during lactation, and at least part of this increase is due to the appearance of the peptide in hypothalamic tuberoinfundibular dopamine neurons, a cell population that does not exhibit NPY expression in other physiological conditions. The present studies tested the hypothesis that NPY affects PRL secretion by modulating the action of dopamine (DA) at the lactotroph. In static incubations of cultured anterior pituitary (AP) cells, the addition of either NPY or DA in concentrations of 0.1-500 nM resulted in dose-dependent inhibition of PRL secretion, and the combination of DA and NPY in submaximal concentrations produced an additive inhibition of PRL release. NPY also inhibited PRL secretion induced by TRH in perifused AP cells, and the effects were again additive with DA. The interactions of NPY and DA on TRH-induced elevations in cytosolic Ca2+ ([Ca2+]i) were examined by loading cultured AP cells of lactating rats with the fluorescent calcium probe fura-2 TRH produced a dose-dependent stimulation of [Ca2+]i, which was characterized by a rapid transient spike and a more prolonged plateau. Both phases were attenuated by either DA or NPY at 100 nM and were nearly abolished by the combination of DA and NPY, whereas neither DA nor NPY altered resting [Ca2+]i. DA and NPY also inhibited the increases in PRL secretion and [Ca2+]i induced by elevated extracellular K+ in an additive manner. Stimulation of AP cells with TRH in the absence of extracellular Ca2+ resulted in an attenuated spike of PRL release and [Ca2+]i and no plateau phase. Under these conditions, DA still inhibited the residual [Ca2+]i and PRL responses, but the inhibitory effects of NPY on PRL secretion and [Ca2+]i, and the potentiation by NPY of DA inhibition, were abolished. These results suggest that one physiological function of the NPY expressed in tuberoinfundibular dopamine neurons in lactation is to amplify the inhibitory action of DA on PRL secretion through negative coupling to the Ca2+ messenger system, particularly the entry of extracellular Ca2+.